EBElizabeth Bautista-Rodríguez

Elizabeth Bautista-Rodríguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Bautista-Rodríguez has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytochemical Characterization and Toxicity Activity of Tradescantia pendula Extracts

    by Rubi Esmeralda González Campos, Elizabeth Bautista Rodríguez, César Emmanuel Ale, Solón Javier Garcés Eisele, Luis Ricardo Hernández, Zaida Nelly Juárez

    Tradescantia pendula is a medicinal plant traditionally used in Mexico to treat inflammatory and infectious conditions. This study evaluated the phytochemical composition, antimicrobial activity, toxicity, and cytotoxicity of T. pendula extracts. Plant material was sequentially extracted using hexane, chloroform, and methanol, followed by phytochemical screening, antimicrobial evaluation against clinically relevant bacterial strains, toxicity assessment using the Artemia salina model, cytotoxicity analysis in HaCaT and U937 cell lines, and GC–MS characterization. Phytochemical screening of the chloroform extract revealed the presence of flavonoids, tannins, triterpenes, and glycosides. Antimicrobial activity was observed mainly against Escherichia coli and Pseudomonas aeruginosa, with bacterial viability reduced by up to 95.2%. Toxicity assays in Artemia salina demonstrated marked biological activity, with LC50 values of 63.54, 23.12, and 23.05 μg/mL for the hexane, chloroform, and methanol extracts, respectively. Cytotoxicity assays revealed cell type-dependent responses, with U937 monocytic cells exhibiting greater sensitivity than HaCaT keratinocytes. All three extracts produced non-monotonic concentration–response profiles, with enhanced metabolic activity at intermediate concentrations and substantial decreases in cell viability at lower concentrations. GC–MS analysis revealed lipophilic metabolites, including phytol-related compounds and fatty acid esters. These findings suggest that T. pendula is a promising source of bioactive metabolites with antimicrobial and cytotoxic properties, supporting its ethnopharmacological relevance and potential pharmacological applications.

  • Open Access

    New Pyridinium Salt Bioconjugates of Cholesterol and Methylpyridine Derivatives: Synthesis and Characterization

    by José María Peña-Martínez, Jesús Alberto Rojas Morales, Luis Ramiro Caso-Vargas, Elizabeth Bautista-Rodríguez, Joel L. Terán, Alan Carrasco-Carballo

    The synthesis of three novel, valuable bioconjugates obtained by coupling cholesterol bromoacetate with pyridine derivatives via an SN2 reaction was successfully carried out. Each of the products was fully characterized by magnetic nuclear resonance (1H, 13C, APT, 1H−1H COSY, 1H–13C HMBC, 1H–13C HSQC), infrared spectroscopy (IR), and high-resolution mass spectrometry (HRMS).

  • Open Access

    Identification and Integration of LRG1-Induced Differentially Expressed Gene (DEG) Hub Profiles in Breast Cancer Cells

    by Federico Osorio-Antonio, Daniela Michel Diaz-González, Gabriela Elizabeth Campos-Viguri, José Manuel Sánchez-López, José Luis Cortez-Sánchez, Francisco Castelán, Jesús Ramses Chávez-Rios, Paola Maycotte-González, Paulina Cortés-Hernández, Oscar Peralta-Zaragoza, et al.

    Breast carcinoma is a major cause of cancer-related mortality among women worldwide. Identifying novel molecular targets remains essential, particularly for aggressive triple-negative breast cancer (TNBC). Leucine-rich alpha-2-glycoprotein 1 (LRG1) has been linked to tumor progression and angiogenesis, but its molecular mechanisms in breast cancer are poorly defined. We evaluated the effects of recombinant human LRG1 (rhLRG1) on cell viability and migration in MDA-MB-231 TNBC cells and performed transcriptomic profiling followed by functional enrichment analyses using GenArise, Cytoscape, and R-based tools. RhLRG1 treatment significantly increased cell viability and migration. Transcriptomic analysis revealed activation of key oncogenic cascades, including the PI3K/AKT, MAPK, and RAS signaling pathways. Hub-gene analysis identified upregulated genes involved in proliferation (NRAS, STAT5B, IGF2), angiogenesis (PGF, ANGPT2), and apoptosis (CASP8, BAD), whereas downregulated genes were associated with apoptotic resistance (BCL2, MCL1) and adhesion (LAMB1, ITGB4). Functional enrichment highlighted LRG1’s role in the bioinformatic analysis of differentially expressed genes that were obtained from microarray assays. LRG1 remodels the tumor microenvironment by promoting proliferation, angiogenesis, and apoptotic sensitivity while repressing resistance-related genes. These findings position LRG1 as a potential diagnostic biomarker and therapeutic target for advanced breast carcinoma.